Spero Therapeutics (SPRO) Revenue (2016 - 2026)
Spero Therapeutics posted quarterly Revenue of $258000.0 for Q1 2026, down 95.61% year-on-year from $5.9 million in Q1 2025, and up 103.51% on a QoQ basis from -$7.3 million in Q4 2025.
Spero Therapeutics (SPRO) has 11 years of Revenue data on file, last reported at $258000.0 in Q1 2026.
- For the quarter ending Q1 2026, Revenue fell 95.61% year-over-year to $258000.0; the trailing twelve-month figure through Mar 2026 stood at $12.5 million (down 70.21% YoY), and the FY2025 full-year result was $12.6 million, down 73.74% from the prior year.
- Revenue for Q1 2026 stood at $258000.0, up from -$7.3 million in the prior quarter.
- Across five years, Revenue topped out at $65.5 million in Q4 2023 and bottomed at -$7.3 million in Q4 2025.
- The 5-year median for Revenue is $2.7 million (2023), against an average of $9.1 million.
- Peak annual rise in Revenue reached 8272.31% in 2025, while the deepest fall reached 124.29% in 2025.
- A 5-year view of Revenue shows it stood at $16.8 million in 2022, then jumped by 290.72% to $65.5 million in 2023, then plunged by 53.84% to $30.3 million in 2024, then slumped by 124.29% to -$7.3 million in 2025, then soared by 103.51% to $258000.0 in 2026.
- The last three Revenue figures came in at $258000.0 (Q1 2026), -$7.3 million (Q4 2025), and $5.4 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 306.30 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 2.99 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 3.61 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 1.17 Bn |
| 10 | Spero Therapeutics | 162.39 Mn | 106.26 Mn | - | 258,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 258,000.00 |
| Dec 31, 2025 | -7.35 Mn |
| Sep 30, 2025 | 5.44 Mn |
| Jun 30, 2025 | 14.19 Mn |
| Mar 31, 2025 | 5.87 Mn |
| Dec 31, 2024 | 30.26 Mn |
| Sep 30, 2024 | 65,000.00 |
| Jun 30, 2024 | 5.90 Mn |
| Mar 31, 2024 | 9.27 Mn |
| Dec 31, 2023 | 65.54 Mn |
| Sep 30, 2023 | 218,000.00 |
| Jun 30, 2023 | 2.72 Mn |
| Mar 31, 2023 | 223,000.00 |
| Dec 31, 2022 | 16.78 Mn |
| Sep 30, 2022 | 2.01 Mn |
| Jun 30, 2022 | 1.99 Mn |
| Mar 31, 2022 | 2.07 Mn |
| Dec 31, 2021 | 15.44 Mn |
| Sep 30, 2021 | 708,000.00 |
| Jun 30, 2021 | 2.11 Mn |
| Mar 31, 2021 | 7.30 Mn |
| Sep 30, 2020 | 38,000.00 |
| Jun 30, 2020 | 1.73 Mn |
| Mar 31, 2020 | 1.70 Mn |
| Dec 31, 2019 | 696,000.00 |
| Sep 30, 2019 | 4.64 Mn |
| Jun 30, 2019 | 67,000.00 |
| Mar 31, 2019 | 7.72 Mn |
| Dec 31, 2018 | 1.69 Mn |
| Sep 30, 2018 | 658,000.00 |
| Jun 30, 2018 | 463,000.00 |
| Dec 31, 2017 | 993,000.00 |
| Sep 30, 2017 | 597,000.00 |
| Jun 30, 2017 | 249,000.00 |
| Mar 31, 2017 | 140,000.00 |
| Dec 31, 2016 | -65,000.00 |
| Sep 30, 2016 | 100,000.00 |